Table 1 Baseline demographic and clinical characteristics of the entire study population
From: Biomarkers of pulmonary hypertension in patients with scleroderma: a case–control study
Pulmonary hypertension (n = 37) | Controls (n = 40) | p value | |
|---|---|---|---|
Sex, n (%) | 1.00 | ||
Male | 3 (8.1) | 4 (10.0) | |
Female | 34 (91.9) | 36 (90.0) | |
Mean age at last sample, yr (range) | 64.9 (38–89) | 55.9 (27–73) | <0.01 |
Race, n (%) | 0.03 | ||
White | 30 (81.1) | 39 (97.5) | |
African American | 7 (18.9) | 1 (2.5) | |
Median disease duration, yr (IQR)a | 10.7 (1.4–16.0) | 8.2 (3.8–9.7) | <0.01 |
Limited SSc, n (%) | 31 (83.8) | 26 (65) | 0.06 |
Ever smoker, n (%) | 12 (32.4) | 15 (37.5) | 0.64 |
Median modified Rodnan skin score (0–51) (IQR) | 7.0 (5.0–15.0) | 7.0 (4.5–18.0) | 0.97 |
Severe Raynaud’s symptoms, n (%)b | 29 (78) | 16 (40) | <0.01 |
FVC, mean±SD | 67.5±21.2 | 88.1±15.9 | <0.01 |
DLCO, mean±SD | 48.4±18.9 (n = 36) | 92.1±24.0 | <0.01 |
Median RVSP (IQR) | 60 (48–74.5) (n = 36) | 33 (27–36) (n = 25) | <0.01 |
Anti-Scl-70, n (%) | 5 (13.5) | 7 (17.5) | 0.63 |
Anti-RNP, n (%) | 4 (11.4) (4/35) | 2 (5.9) (2/34) | 0.67 |
Anti-centromere, n (%) | 17 (46.0) | 13 (32.5) | 0.23 |